Sleep Aid Recommendation for 48-Year-Old Female Without Increased Hunger
For a 48-year-old female seeking a sleep aid that won't increase hunger, I recommend low-dose doxepin (3-6 mg) or a dual orexin receptor antagonist (daridorexant or suvorexant) as first-line pharmacotherapy options, with cognitive behavioral therapy for insomnia (CBT-I) as the foundational treatment.
Rationale and Evidence-Based Approach
Primary Recommendation: Low-Dose Doxepin
Low-dose doxepin emerged as the optimal pharmacotherapy in a 2021 network meta-analysis specifically examining older adults, showing superior efficacy for improving total sleep time (28.19 minutes) and sleep efficiency (6.08%) compared to placebo 1. Critically, low-dose doxepin does not have appetite stimulation as a significant side effect at the 3-6 mg dosing used for insomnia, unlike higher doses used for depression or full-dose tricyclic antidepressants.
Alternative: Dual Orexin Receptor Antagonists
Daridorexant and suvorexant represent newer hypnotic classes that work by blocking orexin receptors involved in wakefulness 2, 3. These medications do not affect appetite or hunger signaling pathways and are much better tolerated than older benzodiazepines, with lower risk of falls, cognitive impairment, and dependence 3. Recent 2026 evidence indicates daridorexant can be discontinued abruptly without withdrawal symptoms 2.
Medications to AVOID
Benzodiazepines and Z-Drugs (Zolpidem, Eszopiclone, Zaleplon)
While the 2017 AASM guidelines recommend benzodiazepine receptor agonists as first-line pharmacotherapy 4, these carry significant risks in middle-aged and older adults including:
- Falls and injuries
- Cognitive impairment
- Dependence and withdrawal symptoms
- Potential increased mortality 3
- Triazolam specifically showed higher adverse event risk 1
Mirtazapine and Other Sedating Antidepressants
Avoid mirtazapine entirely - this is the most important caveat for your patient's specific concern about hunger. Mirtazapine is notorious for causing significant appetite stimulation and weight gain through H1 histamine receptor antagonism and 5-HT2C receptor antagonism. Other sedating antidepressants like trazodone are considered second- or third-line agents with limited evidence 4.
Antihistamines
Over-the-counter antihistamines are not recommended due to lack of demonstrated efficacy and safety concerns 4, though they don't typically increase hunger significantly.
Treatment Algorithm
Start with CBT-I: This is the standard of care with strong guideline support 4 and can be combined with pharmacotherapy
If pharmacotherapy needed:
- First choice: Low-dose doxepin (3-6 mg) - best evidence for efficacy without appetite effects
- Second choice: Daridorexant or suvorexant - newer agents with favorable safety profile and no appetite effects
- Avoid: Benzodiazepines, Z-drugs (especially long-term), and mirtazapine
Duration considerations:
- Short-term use (1-2 weeks) can be discontinued abruptly for orexin antagonists
- Medium to long-term use requires gradual taper (10-25% weekly dose reduction) for most agents except orexin antagonists 2
Key Clinical Pitfalls
- Don't prescribe mirtazapine if appetite/weight concerns exist - this directly contradicts the patient's needs
- Avoid long-term benzodiazepine use due to dependence risk and adverse effects in this age group
- At 48 years old, she's approaching the age where fall risk becomes increasingly relevant with traditional hypnotics
- Always combine pharmacotherapy with CBT-I when possible for best outcomes 4
The evidence strongly supports low-dose doxepin or orexin receptor antagonists as the most appropriate choices that balance efficacy, safety, and the specific requirement of not increasing hunger 1, 3.